Denosumab China Phase III Study

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
This study is to evaluate the efficacy and safety of denosumab 60 milligrams (mg) for 12 month treatment in Chinese postmenopausal women with osteoporosis at increased risk of fracture.
Epistemonikos ID: d09e8a4906483a023dd7ab30e62b51a574383bc6
First added on: May 11, 2024